...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial
fast facts
- name Zenith Epigenetics
- symbol "ZZXY"
- exchange OTCBB
- financials View Filings
- shares outstanding 130,497,528
- industry Technology & Medical
- transfer agent Computershare Trust Company of Canada
- website http://www.zenithepigenet...
recent updates
-
-
-
-
-
Press Release -
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
most recent messages
top rated messages